Hirofumi Tomiyama1, Takahide Kohro2, Yukihito Higashi3, Bonpei Takase4, Toru Suzuki5, Tomoko Ishizu6, Shinichiro Ueda7, Tsutomu Yamazaki8, Tomoo Furumoto9, Kazuomi Kario10, Teruo Inoue11, Shinji Koba12, Kentaro Watanabe13, Yasuhiko Takemoto14, Takuzo Hano15, Masataka Sata16, Yutaka Ishibashi17, Koichi Node18, Koji Maemura19, Yusuke Ohya20, Taiji Furukawa21, Hiroshi Ito22, Hisao Ikeda23, Akira Yamashina24. 1. Department of Cardiology, Tokyo Medical University, Tokyo, Japan. Electronic address: tomiyama@tokyo-med.ac.jp. 2. Department of Clinical Informatics, Jichi Medical University School of Medicine, Tochigi, Japan. 3. Department of Cardiovascular Physiology and Medicine, Hiroshima University Graduate School of Biomedical Science, Hiroshima, Japan. 4. Division of Biomedical Engineering, National Defense Medical College Research Institute, Saitama, Japan. 5. Cardiovascular Medicine, University of Leicester, Leicester, UK. 6. Cardiovascular Division, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan. 7. Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus School of Medicine, Okinawa, Japan. 8. Department of Clinical Epidemiology and Systems, Faculty of Medicine, The University of Tokyo, Tokyo, Japan. 9. Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. 10. Division of Cardiovascular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan. 11. Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan. 12. Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan. 13. Department of Neurology, Hematology, Metaboism, Endocrinology and Diabetology (DNHMED), Yamagata University School of Medicine, Yamagata, Japan. 14. Department of Internal Medicine and Cardiology, Osaka City University Graduate School of Medicine, Osaka, Japan. 15. Department of Medical Education and Population-based Medicine, Postgraduate School of Medicine, Wakayama Medical University, Wakayama, Japan. 16. Department of Cardiovascular Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan. 17. Department of General Medicine, Shimane University Faculty of Medicine, Izumo, Japan. 18. Department of Cardiovascular and Renal Medicine, Saga University, Saga, Japan. 19. Department of Cardiovascular Medicine, Course of Medical and Dental Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan. 20. The Third Department of Internal Medicine, University of the Ryukyus, Okinawa, Japan. 21. Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan. 22. Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan. 23. Department of Medicine, Division of Cardio-Vascular Medicine, Kurume University School of Medicine, Kurume, Japan. 24. Department of Cardiology, Tokyo Medical University, Tokyo, Japan.
Abstract
AIMS: For the standardization of flow-mediated vasodilatation (FMD) assessment as a clinical tool, validation of its reliability across multiple institutions and the establishment of normal/reference values based on reliable data from multiple institutions are needed. METHODS AND RESULTS: In Study 1, assessment of FMD (scan recording and analysis) using an ultrasonographic semi-automatic measuring system (sFMD) was conducted at 18 participating institutions (sFMD-INST) (n = 981). All of the brachial arterial scans were also analyzed at a core laboratory (sFMD-COLB). After 111 subjects with inadequate sFMD recordings were excluded (n = 880), the correlation between the sFMD-INST and sFMD-COLB improved from R = 0.725 to R = 0.838 (p < 0.001). In Study 2, based on good-quality sFMD data obtained from 6660 subjects without cardiovascular disease (CVD) and 729 subjects with CVD from 27 institutions, reference values of sFMD are proposed by the Framingham risk score (FRS)-based risk categories and according to gender and age. The receiver-operating characteristic curve analysis revealed a significant power of sFMD values in reference ranges to discriminate between subjects with and without CVD (e.g., area under curve = 0.64 in the FRS-low risk group). CONCLUSIONS: When the analysis was limited to cases with clear sFMD recordings, the reliability of the sFMD assessment (scan and its analysis) conducted in individual institutions appeared to be acceptable. Reference sFMD values (lower cuff occlusion) for the Japanese population are proposed based on reliable data derived from multiple institutions, and the reference values may identify patients without advanced vascular damage.
AIMS: For the standardization of flow-mediated vasodilatation (FMD) assessment as a clinical tool, validation of its reliability across multiple institutions and the establishment of normal/reference values based on reliable data from multiple institutions are needed. METHODS AND RESULTS: In Study 1, assessment of FMD (scan recording and analysis) using an ultrasonographic semi-automatic measuring system (sFMD) was conducted at 18 participating institutions (sFMD-INST) (n = 981). All of the brachial arterial scans were also analyzed at a core laboratory (sFMD-COLB). After 111 subjects with inadequate sFMD recordings were excluded (n = 880), the correlation between the sFMD-INST and sFMD-COLB improved from R = 0.725 to R = 0.838 (p < 0.001). In Study 2, based on good-quality sFMD data obtained from 6660 subjects without cardiovascular disease (CVD) and 729 subjects with CVD from 27 institutions, reference values of sFMD are proposed by the Framingham risk score (FRS)-based risk categories and according to gender and age. The receiver-operating characteristic curve analysis revealed a significant power of sFMD values in reference ranges to discriminate between subjects with and without CVD (e.g., area under curve = 0.64 in the FRS-low risk group). CONCLUSIONS: When the analysis was limited to cases with clear sFMD recordings, the reliability of the sFMD assessment (scan and its analysis) conducted in individual institutions appeared to be acceptable. Reference sFMD values (lower cuff occlusion) for the Japanese population are proposed based on reliable data derived from multiple institutions, and the reference values may identify patients without advanced vascular damage.
Authors: Shiloh Cleveland; Kristina Reed; Jordan L Thomas; Olujimi A Ajijola; Ramin Ebrahimi; Tzung Hsiai; Amit Lazarov; Amanda K Montoya; Yuval Neria; Daichi Shimbo; Kate Wolitzky-Taylor; Jennifer A Sumner Journal: BMJ Open Date: 2021-05-05 Impact factor: 2.692
Authors: Karsten Königstein; Jonathan Wagner; Denis Infanger; Raphael Knaier; Gilles Nève; Christopher Klenk; Justin Carrard; Timo Hinrichs; Arno Schmidt-Trucksäss Journal: Front Cardiovasc Med Date: 2022-04-28
Authors: Yvonne Alexander; Elena Osto; Arno Schmidt-Trucksäss; Michael Shechter; Danijela Trifunovic; Dirk J Duncker; Victor Aboyans; Magnus Bäck; Lina Badimon; Francesco Cosentino; Marco De Carlo; Maria Dorobantu; David G Harrison; Tomasz J Guzik; Imo Hoefer; Paul D Morris; Giuseppe D Norata; Rosa Suades; Stefano Taddei; Gemma Vilahur; Johannes Waltenberger; Christian Weber; Fiona Wilkinson; Marie-Luce Bochaton-Piallat; Paul C Evans Journal: Cardiovasc Res Date: 2021-01-01 Impact factor: 10.787
Authors: Sophie Lalande; Holden W Hemingway; Caitlin P Jarrard; Amy M Moore; Albert H Olivencia-Yurvati; Rauchelle E Richey; Steven A Romero Journal: Am J Physiol Regul Integr Comp Physiol Date: 2021-07-14 Impact factor: 3.210